2nd Edition of International Conference on Gastroenterology | October 21-23, 2024 | Baltimore, MD, USA

I wish to give you a warm welcome to this year’s meeting in Baltimore and it is my privilege to provide a few comments. Biotechnology stands at the forefront of innovation and progress in the rapidly evolving healthcare technology industry. The commercialization of biotechnology products has transformed healthcare, offering novel solutions to age-old problems and improving patient outcomes. Monoclonal antibodies (mAb) have become a cornerstone of modern medicine, offering targeted precision in treating various diseases. Humira mAb is an example of a biologic that has improved lives of many people around the world. Recombinant biologics are also routinely being used in diagnostic products. Synthetic biology and AI will continue to rapidly expand our ability to make novel molecules for healthcare. CRISPR-Cas9 utilizes a protein called Cas9, which acts like a pair of molecular scissors and can cut DNA. CRISPR-Cas9 therapy was recently FDA approved for the first time for the treatment of sickle cell anemia. Many improvements have been made for vaccines, especially for SARS-CoV-2 RNA vaccines. In addition to healthcare, advances in environmental biotech are helping to create a safer planet by reducing pollution and industrial waste. Agricultural biotech is increasing the worlds food supply through GMO food products by keeping them fresher to increase the shelf life of perishable foods.

2nd Edition of International Conference on Gastroenterology | Baltimore, MD, USA

My two contributions to Gastro 2024 are about new ideas for tackling major, unsolved, global problems in gastric medicine. New ideas need the widest possible audience to reach those few who can take them further, which is why the international reach of Gastro 2024 is so attractive for me. The ideas have profound implications. Gastric medicine is hamstrung without a practical way to measure stomach emptying and motility, much like cardiology would be without electrocardiography. My epigastric impedance monitor can fill that gap by showing how well the stomach is functioning in any clinic anywhere and at low cost.  In digestion I have long wondered why we do not really know how our food passes through the membranes of absorbing cells lining the gut. Now my novel theory of digestion suggests how food might be processed to achieve that by a highly efficient system of enzyme release and control. 

2nd Edition of International Conference on Gastroenterology | Baltimore, MD, USA | October 21-23, 2024

At a time when the Medical and Surgical community is called upon to capitalize on the experiences of the pandemic through the challenges it faces in a health context that is being tested, the Gastro-2024, the 2nd Edition of International Conference on Gastroenterology aims to play an essential and transformative role in the way the medical and surgical professions are organized and operated.

The challenge and the goal for us is to be able to create the necessary framework for a productive scientific dialogue, which touches, through a holistic approach, the practice of the profession in a worldwide context.

Through a multifactorial and multidisciplinary approach, particular emphasis is placed on holistic person-centered models of patient management and precision medicine as they frame modern practice, alongside highlighting the contribution of artificial intelligence, cutting-edge technologies and digital media to the practice of Gastroenterology.

Addressing all the specialties involved, with special emphasis on young doctors who are now training and taking their first steps, special emphasis will be placed on their empowerment.

We invite you to participate and together let us take the next step for our profession and through meaningful interaction with qualified scientists and centers from all over the world, co-shape and create a new approach for the doctor of the future, the perfect scientist, the leader, the human.

2nd Edition of International Conference on Gastroenterology | October 21-23, 2024

Dear congress visitors, it is an honor and a great pleasure for me to extend an invitation to participate in the second edition of our conference. The aim is to address the most recent scientific findings and technical advances, providing a platform for the exchange of knowledge, and fostering collaboration on crucial aspects of research in the field of gastroenterology. Undoubtedly, your participation will enrich the discussions and contribute to the overall success of the conference. We comprehensively evaluated the expression of immune checkpoint molecules on celiac disease. We have focused PI3 expression and discussed it role in regulating the immune response. There is limited data related to the expression or function of this molecule in celiac disease, and it could significantly contribute to the understanding of its clinical manifestation. We propose that alternative splicing of PI3 may be part in the complex pathophysiology in celiac disease patient.

2nd Edition of International Conference on Gastroenterology | Hybrid Event

Delighted to welcome you to this years conference. It is sure to dazzle with the exciting science, innovative discoveries, and pre-clinical work. The topics will cover clinically relevant topics and include a host of investigation into pathology and pathophysiology. The discussion on novel therapeutics and key findings will be invaluable. We have an exciting line up that is sure to capture attention and garnish further collaboration.

International Conference on Gastroenterology | April 20-22, 2023

Dear congress visitors, it is an honor to write a few welcome notes. Immune checkpoint molecules are defined as ligand-receptor pairs that exert inhibitory or stimulatory effects on immune responses. Most of the immune checkpoint molecules are expressed on cells of the adaptive immune system, particularly on T cells, and of the innate immune system. In this study, we focus on the alteration of the Immune checkpoint molecules pathways in celiac disease (CD). CD is a chronic inflammatory disorder with autoimmune disease features that results from a loss of gluten tolerance. Intestinal damage is caused by CD4+T cells, which recognize deamidated gluten peptides presented in complex with HLA-DQ2.5, HLA-DQ2.2, and/or HLA-DQ8. The role of T regulatory  cells in the loss of tolerance to gluten remains poorly understood. The Immune checkpoint molecules may be relevant to the determination of a correlation between markers of the autoimmune response, inflammation, and disease activity.